BOSTON SCIENTIFIC CORP. and BOSTON SCIENTIFIC NEUROMODULATION CORP. v. NEVRO CORP.
Civil Action No. 18-0644-CFC
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
November 25, 2019
COLM F. CONNOLLY, UNITED STATES DISTRICT JUDGE
Counsel for Plaintiffs
Rodger D. Smith, Michael J. Flynn, MORRIS, NICHOLS, ARSHT, & TUNNELL LLP, Wilmington, Delaware; Bradford J. Badke, Ching-Lee Fukuda, Ketan V. Patel, SIDLEY AUSTIN LLP, New York, New York; Thomas A. Broughan III, Sharon Lee, Benjamin H. Huh, SIDLEY AUSTIN LLP, Washington, District of Columbia
Counsel for Defendant
MEMORANDUM OPINION
November 25, 2019
Wilmington, Delaware
COLM F. CONNOLLY
UNITED STATES DISTRICT JUDGE
Plaintiffs Boston Scientific Corporation and Boston Scientific Neuromodulation
I. BACKGROUND1
Boston Scientific is a medical device manufacturer that develops and sells spinal cord stimulation (SCS) systems for the treatment of chronic back pain. D.I. 5 ¶ 12. Boston Scientific launched its first SCS system, the Precision™ System, in 2004 and has since launched four improved Precision™ Systems. Id. ¶ 13. Boston Scientific has obtained several patents covering the core technologies of SCS systems. Id. ¶ 14.
Nevro also produces SCS systems. Id. ¶¶ 15, 17. In the first nine counts of its amended complaint, Boston Scientific alleges that Nevro‘s Senza® Spinal Cord Stimulation System (the Senza I System) and Senza II® Spinal Cord Stimulation System (the Senza II System) infringe nine of Boston Scientific‘s patents: U.S. Patent Nos. 7,496,404 (the #404 patent), 7,127,298 (the #298 patent), 8,682,447 (the #447 patent), 6,993,384 (the #384 patent), 7,853,330 (the #330 patent), 7,822,480 (the #480 patent), 6,381,496 (the #496 patent), 7,177,690 (the #690 patent), and 9,162,071 (the #071 patent). Id. ¶¶ 34–146. All nine counts allege direct, induced, and contributory infringement, and seek enhanced damages for willful infringement. Id. Counts I through IV and VI through VIII also allege export infringement. Id. ¶¶ 40–44, 53–57, 66–67, 79–83, 103–07, 116–20, 129–33.
The accused Senza Systems are devices “designed to deliver electrical stimulation to spinal cord nerves for the treatment of chronic intractable pain.” Id. ¶¶ 15, 17. To deliver stimulation, they use percutaneous leads and “a rechargeable, implantable pulse generator (‘IPG‘).” Id. ¶ 15. “The IPG is transcutaneously recharged using an external charger and is controlled by a patient remote control and/or clinician programmer.” Id. Other components of the Senza Systems “include an external trial stimulator, lead extensions, adaptors, operating room ... cables, and surgical accessories.” Id.
Nevro launched the Senza I System for sale in Europe and Australia in 2011 and in the United States in 2015. Id. ¶ 16. It received regulatory approval to market the Senza II System in Europe in 2017 and in the United States in 2018. Id. ¶ 17.
Boston Scientific also accuses Nevro of trade secret misappropriation under the California Uniform Trade Secret Act (CUTSA) (Count X) and tortious interference with contract (Count XI). Id. ¶¶ 147–77. Both claims are based on Boston Scientific‘s allegation that “one or more of the dozens of former Boston Scientific employees that Nevro has recruited and hired disclosed trade secrets relating to Boston Scientific‘s [SCS] systems to Nevro, in violation of those employees’ contractual obligations.” Id. ¶ 1.
One of the former Boston Scientific employees that Boston Scientific names in the amended complaint is Jim Thacker, Nevro‘s Director of Field Engineering. Id.
Thacker left Boston Scientific in August 2006. Id. ¶ 155. “As part of the exit process,” Thacker acknowledged that “he did not have in his possession any Boston Scientific-owned property.” Id. But on August 18, 2017, Nevro‘s outside counsel informed Boston Scientific that “Thacker in fact took thousands of confidential Boston Scientific documents with him, including five of his own laboratory notebooks detailing the work he performed during the ‘Stimulus’ clinical trials for Boston Scientific‘s Precision™ SCS system.” Id. ¶ 156. The amended complaint further alleges that Thacker took “Boston Scientific-owned thumb drives, actual Precision™ demonstration devices, Physician lead manuals, Physician implant manuals, and Precision™ media kits.” Id.
Boston Scientific alleges that, after taking these confidential and proprietary items, “[o]n multiple occasions, while employed by Nevro, Thacker disclosed Boston Scientific‘s confidential, proprietary information to Nevro.” Id. ¶ 159. Boston Scientific alleges in detail two specific instances when Thacker disclosed such information. The first occurred on April 16, 2009 when Thacker sent to a fellow Nevro employee an email with an attached “Stimulus™ Confirmatory Study” authored by Boston Scientific‘s predecessor, Advanced Bionics. Id. The Confirmatory Study was “Boston Scientific‘s protocol to run the clinical investigation for its Precision™ product.” Id. ¶ 161. It contained confidential information such as “subject enrollment criteria ..., study design,
methodology/testing requirements, and monitoring requirements.” Id. Boston Scientific alleges that the study “would not have been disclosed to anyone not involved with the clinical investigation,” and that each investigator involved in the study agreed to keep confidential all data related to the study. Id.
The second alleged disclosure occurred on May 4, 2009 when Thacker sent to another Nevro employee an email with an attachment titled “Spinal Cord Stimulator Clinician‘s Programming System, Module Specification.” Id. ¶ 163. The Module Specification was “a compilation of information necessary for the design and development of Boston Scientific‘s SCS products.” Id. ¶ 166. Boston Scientific alleges that the specification was a Boston Scientific internal document that included “such confidential information as software functional requirements, including specific programming requirements.” Id.
II. LEGAL STANDARDS FOR STATING A CLAIM
To state a claim on which relief can be granted, a complaint must contain “a short and plain statement of the claim showing that the pleader is entitled to relief.”
570. A claim is facially plausible “when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citation omitted). Deciding whether a claim is plausible is a “context-specific task that requires the reviewing court to draw on its judicial experience and common sense.” Id. at 679 (citation omitted).
III. DISCUSSION
A. Direct Infringement Claims
1. Legal Standards
Liability for direct infringement arises when a party “without authority makes, uses, offers to sell, or sells any patented invention, within the United States or imports into the United States any patented invention during the term of the patent.”
“The complaint must place the potential infringer on notice of what activity is being accused of infringement.” Nalco Co. v. Chem-Mod, LLC, 883 F.3d 1337, 1350 (Fed. Cir. 2018) (internal quotation marks, alterations, and citation omitted). To provide notice, a plaintiff must generally do more than assert that the product infringes the claim; it must show how the defendant plausibly infringes by alleging
some facts connecting the allegedly infringing product to the claim elements. See SIPCO, LLC v. Streetline, Inc., 230 F. Supp. 3d 351, 353 (D. Del. 2017) (granting the motion to dismiss because “[t]he complaint contains no attempt to connect anything in the patent claims to anything about any of the accused products“).
2. Counts I through VII and IX
Counts I through VII and IX each allege infringement of a different patent. D.I. 5 at 12. In each count, Boston Scientific identifies accused products, points to “exemplary materials” extraneous to the amended complaint that provide general information about the accused products, and asserts without explanation that the accused products meet each element of at least one claim of the asserted patent. These allegations fall short of the Iqbal/Twombly pleading standard because they fail to show how the accused products plausibly read on the asserted claim elements.
Specifically, each of the eight counts first alleges that Nevro directly infringes the asserted patent in question by making and selling infringing SCS systems that contain elements recited in a claim. See id. ¶¶ 38, 51, 64, 77, 90, 101, 114, 140. Each count next alleges that “Boston Scientific, through its investigation of the Senza I System ... has determined that the Senza I System meets every element of at least [one or two asserted claims].” Id. ¶¶ 39, 52, 65, 78, 91, 102, 115, 141. For each count, in a footnote to this allegation, Boston Scientific
provides internet links to four pdfs of so-called “[e]xemplary materials“: (1) a four-page letter from the Food and Drug Administration approving Nevro‘s application for commercial distribution of its Senza I System; (2) a 56-page document titled “Summary of Safety and Effectiveness Data” for the Senza I System; (3) a 53-page document titled “Patient Manual” that explains to patients how to use, troubleshoot, and dispose of the Senza I System; and (4) a 31-page document titled
Boston Scientific makes no attempt to connect specific components of the accused systems to elements of the asserted claims. Nor does it explain how any of the 144 pages of linked materials show such a connection. A plaintiff, however, “may not rely on exhibits attached to the complaint as a substitute for pleading facts sufficient to demonstrate its entitlement to relief.” F2VS Techs., LLC v. Aruba Networks, Inc., 2018 WL 1732152, at *2 n.2 (D. Del. Apr. 10, 2018). A
defendant should not be required to comb through 144 pages of exhibits to understand the bases of a plaintiff‘s claims, and a court should not have to parse 144 pages of exhibits to determine if they state facts sufficient to demonstrate a plaintiff‘s entitlement to relief. See id. Accordingly, I will dismiss the direct infringement claims alleged in Counts I through VII and IX.2
3. Count VIII
Boston Scientific alleges in Count VIII that Nevro directly infringes at least claim 1 of the #690 patent by using, making, selling, offering to sell and/or importing infringing SCS systems including the Senza I and II Systems. D.I. 5 ¶¶ 127–28. Claim 1 of the #690 patents recites:
- An implantable medical device system having a replenishing power
source comprising:
an implantable medical device, the device having a housing which contains processing circuitry; and
an external programmer that may be placed in telecommunicative contact with the implantable medical device; and
means for recording battery charging information, which may be recalled later,
wherein the external programmer includes a status indicator for indicating the status of the replenishable power source within the implantable medical device.
#690 patent at claim 1.
Boston Scientific has alleged facts showing that the Senza Systems meet the elements
These factual allegations are sufficient to give Nevro notice of how it may infringe the #690 patent, and thus Boston Scientific has stated a plausible claim for direct infringement in Count VIII.
B. Induced and Contributory Infringement Claims
1. Legal Standards
A plaintiff can prevail on claims of induced and contributory infringement only if it establishes direct infringement. See Limelight Networks, Inc. v. Akamai Techs., Inc., 572 U.S. 915, 921 (2014) (“[I]nducement liability may arise if, but only if, there is direct infringement.” (internal quotation marks, alterations, and citation omitted)); Aro Mfg. Co. v. Convertible Top Replacement Co., 365 U.S. 336, 341 (1961) (“[I]f there is no direct infringement of a patent there can be no contributory infringement.“).
Both “induced infringement [and] contributory infringement require[] knowledge of the patent in suit and knowledge of patent infringement.” Commil USA, LLC v. Cisco Sys., Inc., 135 S. Ct. 1920, 1926 (2015) (citation omitted). For “an allegation of induced infringement to survive a motion to dismiss, a complaint must plead facts plausibly showing that the accused infringer specifically intended [another party] to infringe [the patent] and knew that the [other party]‘s acts constituted infringement.” Lifetime Indus., Inc. v. Trim-Lok, Inc., 869 F.3d 1372, 1379 (Fed. Cir. 2017) (alterations in original) (internal quotation marks and
citation omitted). Contributory infringement requires a showing that the accused infringer “offers to sell or sells ... a component of a patented [invention], ... knowing the same to be especially made or especially adapted for use in an infringement of such patent.”
2. Counts I through VII and IX
patents respectively in Counts I through VII and IX, it cannot plausibly allege that Nevro induced others to infringe the patents or contributed to others’ infringement of them. See Limelight, 572 U.S. at 921; Aro Mfg., 365 U.S. at 341. Accordingly, I will dismiss the claims for induced and contributory infringement alleged in those counts.
3. Count VIII
Boston Scientific has plausibly alleged that Nevro‘s Senza I and II Systems directly infringe the #690 patent, that Nevro marketed and instructed others to use those infringing systems, and that Nevro sold components of the infringing systems. Nevro does not dispute that Boston Scientific has also alleged that Nevro had knowledge of the #690 patent at the time of the alleged infringement. But Boston Scientific has not alleged any facts showing that Nevro knew that its SCS systems infringed the #690 patent. Instead, Boston Scientific‘s allegations regarding Nevro‘s knowledge that the SCS systems infringed the #690 patent are conclusory statements that merely recite the legal requirements for induced and contributory infringement. See D.I. 5 ¶¶ 129, 132.
A complaint must include more than mere “labels and conclusions” or “a formulaic recitation of the elements of a cause of action” to survive a motion to dismiss. Twombly, 550 U.S. at 555 (citation omitted). Thus, Boston Scientific‘s conclusory statements about Nevro‘s knowledge of infringing activity are
insufficient to state a plausible claim. Accordingly, I will dismiss the claims for induced and contributory infringement of the #690 patent in Count VIII.
C. Export Infringement Claims (Counts I through IV and VI through VIII)
Boston Scientific alleges that Nevro infringed seven patents in violation of
D. Enhanced Damages Claims Based on Alleged Willful Infringement
1. Legal Standards
Section 284 of the Patent Act “gives district courts the discretion to
court may increase the damages up to three times the amount found or assessed.”
Although “§ 284 allows district courts to punish th[is] full range of culpable behavior,” id. at 1933, in the vast majority of patent cases filed today, claims for enhanced damages are sought based on allegations of willful misconduct—so much so that, even though the words “willful” and “willfulness” do not appear in § 284, plaintiffs and courts more often than not describe claims for enhanced
damages brought under § 284 as “willful infringement claims” (just as the parties have done in this case). Indeed, some parties and courts refer to such claims as willful infringement “causes of action” even though § 271 of the Patent Act, which creates causes of action for direct, induced, and contributory infringement, does not mention or suggest such a thing as “willful infringement.”4
The fact that willfulness is the most common type of misconduct alleged by plaintiffs who invoke § 284 makes sense, as willful conduct “serve[s] as [the] floor for culpable behavior that may incur enhanced damages.” ROBERT L. HARMON, CYNTHIA A. HOMAN & LAURA A. LYDIGSEN, PATENTS AND THE FEDERAL CIRCUIT, § 17.3(a), at 1378 (13th ed. 2017). It also explains the Court‘s statement in Halo that enhanced damages under § 284 “should generally be reserved for egregious cases typified by willful misconduct.” 136 S. Ct. at 1934 (emphasis added).
In assessing the egregiousness of a defendant‘s conduct for § 284 purposes, “culpability is generally measured against the knowledge of the [defendant] at the time of the challenged conduct.” Id. at 1933. The Court in Halo rejected the Federal Circuit‘s requirement announced in In re Seagate Technology, LLC, 497 F.3d 1360 (Fed. Cir. 2007) (en banc) that a patentee show “objective recklessness” in order to prove willful misconduct for § 284 purposes. The Court reasoned that the “objective recklessness” test insulated many of the most culpable infringers from § 284‘s punitive sanctions because it made dispositive invalidity and noninfringement defenses asserted at trial even if the infringer had not acted on the basis of those defenses or was even aware of them. In the Court‘s words: “Under that standard, someone who plunders a patent—infringing it without any reason to suppose his conduct is arguably defensible—can nevertheless escape any comeuppance under § 284 solely on the strength of his attorney‘s ingenuity.” Halo, 136 S. Ct. at 1933. Thus, the Court held that, in cases where the asserted basis for enhanced damages is willful misconduct, it is “[t]he subjective willfulness of [the] patent infringer, intentional or knowing, [that] may warrant enhanced damages, without regard to whether his infringement was objectively reckless.” Id.
The Court‘s “intentional or knowing” clause makes clear that willful infringement is—at a minimum—knowing infringement. This standard is
consistent with the Supreme Court‘s holding in Global-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754, 766 (2011) that “induced infringement under § 271(b) requires knowledge that the induced acts constitute patent infringement.” Since § 284 enhanced damages are available in cases of induced infringement, see, e.g., Barry v. Medtronic, Inc., 2019 WL 302886, at *17 (Fed. Cir. Jan. 24, 2019); SynQor, Inc. v. Artesyn Techs., Inc., 709 F.3d 1365, 1385 (Fed. Cir. 2013); ACCO Brand, Inc. v. ABA Locks Mfrs. Co., 501 F.3d 1307, 1314 (Fed. Cir. 2007); Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1371 (Fed. Cir. 2004), and since, under Halo, § 284‘s enhanced damages award is reserved only for egregious cases, it would seem incongruous if not illogical to require a lesser showing of culpability for enhanced damages under § 284 than for induced infringement under § 271(b).
The Federal Circuit recently emphasized in SRI International, Inc. v. Cisco Systems, Inc., 930 F.3d 1295 (Fed. Cir. 2019) that under Halo enhanced damages are available only if a showing of something more than intentional or knowing infringement is made:
As the Supreme Court stated in Halo, “[t]he sort of conduct warranting enhanced damages has been variously described in our cases as willful, wanton, malicious, bad-faith, deliberate, consciously wrongful, flagrant, or—indeed—characteristic of a pirate.” While district courts have discretion in deciding whether or not behavior rises to that standard, such findings “are generally reserved for egregious cases of culpable
behavior.” Indeed, as Justice Breyer emphasized in his concurrence, it is the circumstances that transform simple “intentional or knowing” infringement into egregious, sanctionable behavior, and that makes all the difference.
Id. (emphasis in original) (citations omitted).5
beyond the pleadings stage if the operative pleading alleges facts from which it can be plausibly inferred that the party accused of infringement had knowledge of the asserted patent and knowledge that the party‘s alleged conduct constituted, induced, or contributed to infringement of the asserted patent. And since the doctrine of willful blindness applies in patent cases, see Global-Tech, 563 U.S. at 766, a willful infringement-based claim for enhanced damages survives a motion to dismiss if it alleges facts from which it can be plausibly inferred that the party accused of infringement (1) had knowledge of or was willfully blind to the existence of the asserted patent and (2) had knowledge of or was willfully blind to the fact that the party‘s alleged conduct constituted, induced, or contributed to infringement of the asserted patent.
2. Discussion
The parties do not dispute that Boston Scientific has plausibly alleged that Nevro had knowledge of the asserted patents at the time of the alleged infringement. Boston Scientific, however, has not alleged any facts showing that Nevro knew that its SCS systems infringed the asserted patents; rather, it merely states in each count that “Nevro‘s infringement is reckless, knowing, deliberate, and willful.” D.I. 5 ¶¶ 45, 58, 71, 84, 95, 108, 121, 134, 145. Such conclusory statements are insufficient to plead a cognizable claim. See Twombly, 550 U.S. at 555. Accordingly, I will dismiss its claims for enhanced damages.
E. CUTSA Trade Secret Misappropriation Claim (Count X)
1. Legal Standards
To state a claim for trade secret misappropriation under the CUTSA, a plaintiff must allege that “(1) the plaintiff owned a trade secret, (2) the defendant acquired, disclosed, or used the plaintiff‘s trade secret through improper means, and (3) the defendant‘s actions damaged the plaintiff.” Mintz v. Mark Bartelstein & Assocs. Inc., 906 F. Supp. 2d 1017, 1038 (C.D. Cal. 2012) (citations omitted).
To establish that it owned a trade secret, a plaintiff must show (1) that the subject of the trade secret was not “generally known to the public or to other persons who [could] obtain economic value from its disclosure or use” and (2) that plaintiff took reasonable efforts “under the circumstances to maintain [the trade secret‘s] secrecy.” See
To prove misappropriation, the plaintiff must show (1) that “the defendant acquired, disclosed, or used the plaintiff‘s trade secret through improper means,” CytoDyn, Inc. v. Amerimmune Pharm., Inc., 160 Cal. App. 4th 288, 297 (2008), and (2) that the defendant knew or had reason to know that it was “not in rightful possession of the information,” Cypress Semiconductor Corp. v. Superior Court, 163 Cal. App. 4th 575, 585 (2008).
2. Identification of The Alleged Trade Secrets
Nevro argues that the amended complaint fails to allege the existence of a trade secret for three reasons: (1) a California court previously rejected Boston Scientific‘s claims that the documents in question should have been sealed in a court filing because they contain trade secrets, D.I. 11 at 18; (2) Boston Scientific “fails to separate [its alleged trade secrets] from matters of general knowledge in the trade,” id., and (3) the contents of the Confirmatory Study document that Thacker emailed to his Nevro colleague were disclosed four years before his email when the National Institute of Health (NIH) published the results of the study underlying the document, id. at 19. All three arguments lack merit.
First, Nevro‘s reliance on another court‘s ruling is improper in the context of a Rule 12(b)(6) motion. It is black letter law that a district court “may not consider matters extraneous to the pleadings” when ruling on a motion to dismiss. In re
Burlington Coat Factory Sec. Litig., 114 F.3d 1410, 1426 (3d Cir. 1997).6
Second, the amended complaint identifies the alleged trade secrets with sufficient particularity to separate them from knowledge in the trade. Specifically, the amended complaint alleges that (1) Thacker sent emails to Nevro employees containing the “Stimulus™ Confirmatory Study” and the “Spinal Cord Stimulator Clinician‘s Programming System, Module Specification,” D.I. 5 ¶¶ 159, 163; (2) the Confirmatory Study was “Boston Scientific‘s protocol to run the clinical investigation for its Precision™ product” and it included “such confidential information as subject enrollment criteria ..., study design, methodology/testing requirements, and monitoring requirements,” id. ¶ 161; and (3) the Module Specification was a Boston Scientific internal document with “information necessary for the design and development of Boston Scientific‘s SCS products, and include[d] such confidential
the trade or special knowledge of those persons skilled in the trade. It thus provides sufficient particularity to survive a motion to dismiss.
Third, assuming arguendo that I could take judicial notice of the NIH publication of the results of the study underlying the Confirmatory Study document for purposes of deciding this motion, the amended complaint alleges that Thacker emailed his Nevro colleagues other documents that contained trade secrets that were not disclosed by the NIH. Moreover, the amended complaint alleges that the Confirmatory Study “would not have been disclosed to anyone not involved with the clinical investigation,” id. ¶ 161, and I must accept for Rule 12(b)(6) purposes that the allegations in the amended complaint are true.
3. Knowing Acquisition, Disclosure, or Use of the Trade Secrets through Improper Means
Nevro also argues that Boston Scientific has not plausibly alleged that Nevro knew about the alleged trade secrets or that it acquired, disclosed, or used those trade secrets through improper means. D.I. 11 at 17. But the amended complaint specifically alleges that Thacker provided the Confirmatory Study and the Module Specification to Nevro employees and that both the study and the specification were marked in a manner that made clear their propriety and confidential nature. See D.I. 5 ¶ 160 (alleging that the Confirmatory Study had the following warning typed in bold on every page: “Proprietary information of Advanced Bionics. Subject to terms of Non-Disclosure Agreement“); id. ¶ 164 (alleging that the
Module Specification contained the word “CONFIDENTIAL” on the front page in bold and had the following message: “This document contains confidential information and is proprietary to Advanced Bionics corporation and may not be distributed or reproduced without the prior express written consent of Advanced Bionics“). Thus, the amended complaint alleges facts from which it can plausibly be inferred that Nevro knowingly acquired Boston Scientific‘s trade secrets.
The amended complaint also alleges facts from which it can be plausibly inferred that Nevro used these trade secrets. Specifically, it alleges that the Confirmatory Study‘s internal investigation protocol for its Precision™ SCS product and the Module Specification‘s internal information for the design and development of Boston Scientific‘s SCS products would have been valuable to Nevro, “who during the relevant time period was developing its own SCS system, and conducting its own clinical investigations.” Id. ¶ 162; see also id. ¶ 167. And it alleges that “[s]ince Nevro had never developed an SCS product before, the Stimulus Confirmatory Study disclosed by Mr. Thacker provided Nevro with a necessary tool to develop its own clinical investigation protocol.” Id. ¶ 162.
F. Tortious Interference with Contract Claim (Count XI)
Finally, in Count XI Boston Scientific accuses Nevro of tortious interference with contract. Nevro argues that I should dismiss the claim because it is preempted by Boston Scientific‘s trade secret claim and is insufficiently pled. D.I. 11 at 19,
20. Because I agree that Boston Scientific has not pled sufficient facts to state a plausible claim for tortious interference, I will dismiss the claim without addressing Nevro‘s argument that the claim is preempted.
To state a claim under California law for tortious interference with contract, a plaintiff must plausibly allege: “(1) a
Although Boston Scientific has alleged facts that plausibly show elements one, two, four, and five, it has not alleged any facts regarding element three—i.e., it has not alleged facts that plausibly show that Nevro intentionally acted “to induce a breach or disruption of the contractual relationship” between Thacker and Boston Scientific. As Boston Scientific itself acknowledges, the only “intentional act” it alleges consistent with element three appears in the following statement from the amended complaint: “Upon information and belief, Nevro intentionally, and in violation of applicable law, interfered with the contract between Mr. Thacker and Boston Scientific by encouraging Mr. Thacker to breach his contract with Boston Scientific and/or disrupt the contractual relationship between Mr.
Thacker and Boston Scientific.” D.I. 12 at 20 (citing D.I. 5 ¶ 176). Such a conclusory allegation that is essentially a “formulaic recitation of the elements of a cause of action” is insufficient to plead a cognizable claim. Twombly, 550 U.S. at 555. Accordingly, I will dismiss Count XI.
IV. CONCLUSION
For the foregoing reasons, I will grant-in-part and deny-in-part Nevro‘s motion. I will grant Nevro‘s motion insofar as it seeks dismissal of the direct infringement claims alleged in Counts I through VII and IX but will deny the motion insofar as it seeks dismissal of the direct infringement claim alleged in Count VIII. I will grant the motion insofar as it seeks to dismiss Boston Scientific‘s claims for induced infringement, contributory infringement, and enhanced damages based on willful infringement. I will deny the motion insofar as it seeks dismissal of Boston Scientific‘s claims for export infringement and trade secret misappropriation. And I will grant the motion insofar as it seeks dismissal of the tortious interference of contract claim in Count XI. Finally, I will reduce by 1,000 the number of words Nevro can use in the brief it files in support of its next motion in this case.
The Court will enter an order consistent with this Memorandum Opinion.